Trial Profile
Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention.(Molecole di Adesione Nella Sindrome Coronarica Acuta)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Abciximab (Primary) ; Abciximab (Primary)
- Indications Embolism and thrombosis; Myocardial infarction
- Focus Biomarker; Pharmacodynamics
- 22 Jan 2013 New trial record